Suppr超能文献

在原发性骨质疏松症或雌激素替代治疗后,骨骼对甲状腺激素的反应性是否会发生改变?

Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?

作者信息

Langdahl B L, Loft A G, Møller N, Weeke J, Eriksen E F, Mosekilde L, Charles P

机构信息

Aarhus Bone and Mineral Research Group, University Department of Endocrinology and Metabolism, Denmark.

出版信息

J Bone Miner Res. 1997 Jan;12(1):78-88. doi: 10.1359/jbmr.1997.12.1.78.

Abstract

Hyperthyroidism is characterized by increased bone turnover and resorptive activity. Similar changes in remodeling are seen in osteoporosis. To study the pathogenetic role of thyroid hormone in osteoporosis, we measured concentrations of free and total thyroid hormones and investigated the sensitivity of the skeleton toward thyroid hormones in 14 osteoporotic, 16 estrogen-treated, and 15 normal postmenopausal women with comparable thyroid status. Triiodothyronine (T3, 60 microg/day for 7 days) was administered to the three groups. The skeletal response was assessed by monitoring bone alkaline phosphatase (BAP), osteocalcin (BGP), and pyridinium cross-linked telopeptide domain of type I collagen (ICTP) in serum and urinary excretion of hydroxyproline (OHP), pyridinoline (PYR), and deoxypyridinoline (DPR) at days 0, 8, 15, and 57. Women on estrogen replacement therapy exhibited lower bone turnover than the normal postmenopausal women. Markers of bone formation were reduced by 19-43% and markers of resorption by 22-48%. The osteoporotic women displayed lower bone mass at the lumbar spine and the distal forearm (p < 0.01-0.001), but the levels of biochemical markers of bone formation and resorption were comparable to values obtained in the normal postmenopausal women. T3 stimulation caused significant increases (p values ranging between 0.05-0.001) in all three groups of the resorptive markers: ICTP (47%, 47%, 45%), OHP (29%, 30%, 33%), PYR (43%, 27%, 51%), and DPR (42%, 24%, 59%). Of the formative markers, only BGP increased significantly (32%, 40%, 47%) (p < 0.001). At day 57, however, all three formative markers increased compared with day 15 (p < 0.05-0.001). No significant differences in bone markers were demonstrated between groups. In the osteoporotic group, as the only group, serum calcium increased (p < 0.05) and serum PTH fell (p < 0.05). In conclusion, osteoporosis and estrogen substitution are not characterized by altered concentrations of thyroid hormones or responsiveness to thyroid hormones at the level of individual bone cells; however, altered responses pertaining to PTH and calcium were detected.

摘要

甲状腺功能亢进的特征是骨转换和吸收活性增加。骨质疏松症也有类似的重塑变化。为了研究甲状腺激素在骨质疏松症发病机制中的作用,我们测量了14名骨质疏松症患者、16名接受雌激素治疗的患者和15名甲状腺状态相当的正常绝经后女性的游离和总甲状腺激素浓度,并研究了骨骼对甲状腺激素的敏感性。三组患者均给予三碘甲状腺原氨酸(T3,60μg/天,共7天)。通过监测第0、8、15和57天血清中的骨碱性磷酸酶(BAP)、骨钙素(BGP)和I型胶原吡啶交联端肽结构域(ICTP)以及羟脯氨酸(OHP)、吡啶啉(PYR)和脱氧吡啶啉(DPR)的尿排泄来评估骨骼反应。接受雌激素替代治疗的女性骨转换低于正常绝经后女性。骨形成标志物降低了19%-43%,吸收标志物降低了22%-48%。骨质疏松症女性腰椎和前臂远端的骨量较低(p<0.01-0.001),但其骨形成和吸收的生化标志物水平与正常绝经后女性相当。T3刺激导致三组吸收标志物均显著增加(p值在0.05-0.001之间):ICTP(47%、47%、45%)、OHP(29%、30%、33%)、PYR(43%、27%、51%)和DPR(42%、24%、59%)。在形成标志物中,只有BGP显著增加(32%、40%、47%)(p<0.001)。然而,在第57天,与第15天相比,所有三种形成标志物均增加(p<0.05-0.001)。各组之间骨标志物无显著差异。在骨质疏松症组中,作为唯一的一组,血清钙升高(p<0.05),血清甲状旁腺激素下降(p<0.05)。总之,骨质疏松症和雌激素替代在个体骨细胞水平上的特征不是甲状腺激素浓度改变或对甲状腺激素的反应性改变;然而,检测到与甲状旁腺激素和钙有关的反应改变。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验